However, a study published in 2023 investigated whether the novel glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist DA4-JC provided protective effects in the triple APP/PS1/tau mouse model of AD using in vivo LTP recordings of the hippocampus, biochemical analyses of biomarkers, and quantified synapses using the Golgi method. Here, MAPT is linked to Alzheimer disease.